tiprankstipranks
Trending News
More News >
Sumitomo Chemical Co (JP:4005)
:4005
Advertisement

Sumitomo Chemical Co (4005) AI Stock Analysis

Compare
1 Followers

Top Page

JP:4005

Sumitomo Chemical Co

(OTC:4005)

Rating:54Neutral
Price Target:
¥374.00
▼(-6.50% Downside)
Sumitomo Chemical's overall stock score reflects a challenging financial environment with mixed financial performance and a high valuation. Technical indicators suggest moderate positive momentum, but the high P/E ratio raises concerns about overvaluation. The earnings call highlighted both operational improvements and significant financial challenges, particularly from currency fluctuations and declining sales revenue.

Sumitomo Chemical Co (4005) vs. iShares MSCI Japan ETF (EWJ)

Sumitomo Chemical Co Business Overview & Revenue Model

Company DescriptionSumitomo Chemical Company, Limited engages in the petrochemicals and plastics, energy and functional materials, IT-related chemicals, health and crop sciences, pharmaceuticals, and other businesses worldwide. Its Petrochemicals & Plastics segment offers synthetic resins, such as polyethylene, polypropylene, and polymethyl methacrylate resins; raw materials for synthetic fibers; and various industrial chemicals. The company's Energy & Functional Materials segment provides alumina and aluminum products used for energy products; polymer additives and rubber chemicals; synthetic rubber for tires, shoes, construction materials, and other applications; and engineering plastics and lithium-ion secondary battery materials for use in electronic components and next-generation vehicles. Its IT-Related Chemicals segment provides polarizing films, touch screen sensor panels, and color resists for LC and OLED displays; photoresists and high-purity chemicals for semiconductor manufacturing process; and compound semiconductor materials for antenna switches and other components of communication terminal equipment. The company's Health & Crop Sciences segment offers crop protection chemicals, fertilizers, feed additives, and household insecticides; active pharmaceutical ingredients and intermediates; and products to control infectious diseases. Its Pharmaceuticals segment provides prescription and diagnostic pharmaceuticals. The company's Others segment supplies electric power and steam; designs, constructs, and supervises chemical plants; provides transportation and warehousing services; and conducts physical property and environmental analysis. It has collaboration with Ginkgo Bioworks Announces Sumitomo Chemical to develop bio-based chemicals. Sumitomo Chemical Company, Limited was founded in 1913 and is headquartered in Tokyo, Japan.
How the Company Makes MoneySumitomo Chemical Co., Ltd. generates revenue through the production and sale of a broad spectrum of chemical products across its various business segments. The company's revenue streams are diversified, including sales from petrochemicals like synthetic resins and plastics, which are used in manufacturing and industrial applications. In the health and crop sciences sector, Sumitomo Chemical earns income from agrochemicals, which are critical for the agriculture industry, as well as pharmaceuticals that serve the healthcare market. The IT-related chemicals segment offers products such as photoresists and high-purity chemicals essential for semiconductor and display manufacturing. Additionally, strategic partnerships and investments in research and development enhance the company's product offerings and competitive position, further contributing to its earnings.

Sumitomo Chemical Co Earnings Call Summary

Earnings Call Date:Aug 01, 2025
(Q1-2025)
|
% Change Since: 5.35%|
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Neutral
The earnings call for FY2025 Q1 presented a mixed picture. While there were significant improvements in core operating income and positive developments in the Sumitomo Pharma and Essential and Green Materials segments, the company faced challenges with declining sales revenue, net income loss, and negative free cash flow. The impact of foreign currency fluctuations also posed a significant hurdle.
Q1-2025 Updates
Positive Updates
Core Operating Income Increase
Core operating income for FY2025 Q1 was JPY27.7 billion, up JPY22 billion YoY, indicating strong recurring earnings power.
Sumitomo Pharma Performance
Sumitomo Pharma's core operating income was JPY21 billion, an increase of JPY20.1 billion YoY, driven by increased shipments and operational streamlining.
Essential and Green Materials Improvement
Core operating income improved by JPY14.1 billion YoY, with profit margins improved in synthetic resins due to naphtha price drop and improved refining margins at Petro Rabigh.
Positive Cash Flow from Operating Activities
Cash flows from operating activities resulted in a positive inflow of JPY24 billion, up by JPY36.3 billion YoY, improving working capital.
Negative Updates
Sales Revenue Decline
Sales revenue was JPY526.1 billion, down JPY86 billion YoY, with decreases in all segments except Sumitomo Pharma due to lower sales prices and volume.
Net Income Loss
Net income attributable to owners of the parent for the quarter was a loss of JPY4.5 billion, down JPY28.9 billion YoY, impacted by foreign currency losses.
Finance Income Decline
Finance income had a loss of JPY19.6 billion, down JPY45.6 billion YoY, with foreign currency transactions resulting in a JPY16.4 billion loss due to yen appreciation.
Negative Free Cash Flow
Free cash flows were negative JPY21.9 billion, a deterioration of JPY92.2 billion compared to the previous year, impacted by decreased cash flows from investing activities.
Challenges in ICT and Mobility Solutions
Core operating income was down JPY2.8 billion YoY, with lower income from exports due to stronger yen offsetting gains from the sale of the large LCD polarizing film business.
Company Guidance
During the Q1 FY2025 conference call, Mr. Toshihiro Yamauchi provided a detailed overview of the company's financial performance and guidance. Sales revenue was reported at JPY526.1 billion, marking a YoY decrease of JPY86 billion, while core operating income rose by JPY22 billion YoY to JPY27.7 billion. Non-recurring items saw a loss of JPY2.2 billion, contributing to an overall operating income of JPY25.5 billion, up JPY14 billion YoY. The net income attributable to owners of the parent was a loss of JPY4.5 billion, a decline of JPY28.9 billion YoY. The company faced challenges due to the appreciation of the yen and fluctuations in naphtha prices, with the average exchange rate at JPY144.59 to USD1. The outlook for H1 FY2025 projects sales revenue of JPY1.1 trillion, a decrease of JPY141.4 billion YoY, and a core operating income of JPY90 billion, up JPY60.5 billion YoY. The company expects strong performance from Sumitomo Pharma and anticipates improvements in profitability for essential and green materials, despite ongoing challenges in the ICT and mobility solutions segment due to exchange rate impacts.

Sumitomo Chemical Co Financial Statement Overview

Summary
Sumitomo Chemical is navigating a challenging financial landscape with mixed performance across key financial metrics. While there is a solid asset base, profitability and cash flow stability need attention. Strategic focus on managing debt and improving operational efficiency could enhance financial health.
Income Statement
45
Neutral
Sumitomo Chemical's income statement shows moderate performance with some volatility. The gross profit margin has been relatively stable, but the company experienced significant fluctuations in net income resulting in negative net profit margins in recent years. Revenue growth has been inconsistent, and EBIT margins reflect a challenging operating environment.
Balance Sheet
55
Neutral
The balance sheet indicates a strong asset base with stable equity levels, but the debt-to-equity ratio is relatively high, suggesting significant leverage. Return on equity has been volatile due to fluctuating net income, impacting overall financial stability.
Cash Flow
50
Neutral
Cash flow analysis reveals volatile free cash flow figures with recent improvement. Operating cash flow has been inconsistent, affecting the company’s ability to cover net income effectively. There is potential for improvement if current free cash flow trends continue.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.61T2.45T2.90T2.77T2.29T
Gross Profit725.48B499.69B820.93B873.86B771.20B
EBITDA321.64B-258.31B199.08B388.68B306.28B
Net Income38.59B-311.84B6.99B162.13B46.04B
Balance Sheet
Total Assets3.44T3.93T4.17T4.31T3.99T
Cash, Cash Equivalents and Short-Term Investments209.84B217.45B337.08B389.42B373.73B
Total Debt1.29T1.56T1.46T1.35T1.35T
Total Liabilities2.37T2.77T2.68T2.61T2.51T
Stockholders Equity900.79B965.75B1.17T1.22T1.02T
Cash Flow
Free Cash Flow102.56B-204.19B-31.96B64.25B253.65B
Operating Cash Flow233.03B-51.32B111.62B171.72B374.46B
Investing Cash Flow85.23B-112.24B-19.41B-115.42B-177.39B
Financing Cash Flow-300.78B49.25B-178.50B-81.39B-39.97B

Sumitomo Chemical Co Technical Analysis

Technical Analysis Sentiment
Positive
Last Price400.00
Price Trends
50DMA
357.09
Positive
100DMA
348.43
Positive
200DMA
352.19
Positive
Market Momentum
MACD
10.13
Negative
RSI
70.53
Negative
STOCH
78.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4005, the sentiment is Positive. The current price of 400 is above the 20-day moving average (MA) of 375.17, above the 50-day MA of 357.09, and above the 200-day MA of 352.19, indicating a bullish trend. The MACD of 10.13 indicates Negative momentum. The RSI at 70.53 is Negative, neither overbought nor oversold. The STOCH value of 78.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4005.

Sumitomo Chemical Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (44)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
¥654.98B67.600.92%2.25%0.98%
44
Neutral
C$874.34M-6.79-14.91%2.76%16.69%-26.66%
$10.17B12.406.55%3.56%
$3.66B40.132.06%3.03%
$7.46B43.331.29%4.04%
€4.18B15.3120.91%
$59.33B16.6812.25%2.44%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4005
Sumitomo Chemical Co
400.00
-20.14
-4.79%
AHKSF
Asahi Kasei
7.50
1.20
19.05%
KURRF
Kuraray Co
12.75
1.31
11.45%
MTLHF
Mitsubishi Chemical Holdings
5.38
-0.13
-2.36%
DE:NSC
Nissan Chemical
31.20
3.44
12.39%
SHECF
Shin-Etsu Chemical Co
29.44
-9.27
-23.95%

Sumitomo Chemical Co Corporate Events

Sumitomo Chemical Reports Q1 Foreign Exchange Loss
Aug 1, 2025

Sumitomo Chemical Co., Ltd. reported a foreign exchange loss of ¥18,427 million for the first quarter of fiscal year 2025 due to fluctuations in foreign exchange rates affecting assets and liabilities in foreign currencies. This financial impact is detailed in the company’s consolidated financial results, highlighting the challenges posed by currency volatility on its operations.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

Sumitomo Chemical Reports Q1 FY2025 Financial Results
Aug 1, 2025

Sumitomo Chemical Co. reported its consolidated financial results for the first quarter of fiscal year 2025, showing a significant decrease in sales revenue by 14% compared to the previous year. Despite the decline in sales, the company achieved a substantial increase in core operating income by 388.2%, indicating improved operational efficiency. However, net income attributable to owners of the parent fell by 88.6%, reflecting challenges in the market. The company also announced its financial forecast for the first half of fiscal year 2025, maintaining its full-year forecast unchanged.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

Sumitomo Chemical Completes Strategic Share Transfer in Asian Business
Jul 31, 2025

Sumitomo Chemical Co., Ltd. has completed a company split and share transfer involving its subsidiary, Sumitomo Pharma Co., Ltd., transferring 60% of its new Asian business subsidiary to Marubeni Global Pharma Inc. This strategic move is expected to generate approximately 45 billion yen in other operating income for Sumitomo Chemical, which will be used to strengthen its financial foundation and focus on growth initiatives.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen430.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

Sumitomo Chemical Completes Restricted Stock Compensation Issuance
Jul 18, 2025

Sumitomo Chemical Co., Ltd. has completed the payment procedure for the issuance of new shares as restricted stock compensation, as resolved in their June 2025 Board of Directors meeting. This issuance involves 696,791 shares of common stock at 344 yen per share, amounting to a total of 239,696,104 yen, and is aimed at compensating select members of the company’s Board of Directors and executive officers, potentially impacting the company’s governance and stakeholder alignment.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen360.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

Sumitomo Chemical Announces New Share Issuance for Restricted Stock Compensation
Jun 20, 2025

Sumitomo Chemical Co., Ltd. has announced the issuance of new shares as part of its Restricted Stock Compensation Plan, aimed at incentivizing its board members and executive officers to enhance corporate value. The plan involves issuing 696,791 shares at 344 yen per share, with a total issuance amount of 239,696,104 yen, and is designed to align the interests of eligible officers with those of shareholders through restricted stock allotments.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

Sumitomo Chemical Announces Leadership Change
May 14, 2025

Sumitomo Chemical Co., Ltd. has announced a change in its leadership, appointing Keigo Sasaki as the new Representative Director. This decision, aimed at strengthening the company’s management structure, will be finalized at the upcoming General Meeting of Shareholders and subsequent Board of Directors meeting.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

Sumitomo Chemical Proposes Amendments to Enhance Governance
May 14, 2025

Sumitomo Chemical Co., Ltd. has announced a proposal for partial amendments to its Articles of Incorporation, which will be discussed at the upcoming General Meeting of Shareholders on June 20, 2025. The proposed changes include transitioning to a company with an Audit and Supervisory Committee, establishing new provisions for directors and decision-making processes, and allowing for more flexible resolutions by the Board of Directors. These amendments aim to enhance the company’s governance structure and operational flexibility.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

Sumitomo Chemical Reports Impairment and Forex Losses in Q4 FY2024
May 14, 2025

Sumitomo Chemical Co., Ltd. announced significant impairment losses and finance expenses for the fourth quarter of FY2024. The impairment losses, totaling ¥20,802 million, were primarily due to decreased profitability in their advanced medical solutions and essential materials sectors, as well as the devaluation of patent rights. Additionally, a foreign exchange loss of ¥26,342 million was recorded, impacting the company’s financial results due to fluctuations in foreign currency valuations.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

Sumitomo Chemical Reports Strong FY 2024 Financial Results
May 14, 2025

Sumitomo Chemical Co. reported its consolidated financial results for the fiscal year 2024, highlighting a significant improvement in financial performance compared to the previous year. The company achieved a sales revenue of ¥2,606,281 million, marking a 6.5% increase from FY 2023, and a notable recovery in net income attributable to owners of the parent, which stood at ¥38,591 million. This positive financial outcome reflects the company’s strategic efforts to enhance its operational efficiency and market positioning, benefiting stakeholders and reinforcing its industry standing.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

Sumitomo Chemical Reports Financial Variances in Subsidiaries
May 13, 2025

Sumitomo Chemical Co. reported variances in the non-consolidated financial results of its subsidiaries for fiscal years 2024 and 2023. Sumitomo Pharma Co., Ltd. saw significant improvements in net sales and income due to increased sales in North America and China, alongside reduced expenses. Taoka Chemical Co., Ltd. experienced growth in sales and income driven by higher sales of resin raw materials and cost-cutting measures. The overall impact on Sumitomo Chemical’s consolidated financial forecast is considered immaterial.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen370.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 02, 2025